Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 -2.50%73 Quick Ratio is 17.03 as of Dec. 2025, which is 11% below its 10-year median of 19.08. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, BioGend Therapeutics Co ranks better than 89.51% on this metric.
BioGend Therapeutics Co has a quick ratio of 17.03. It generally indicates good short-term financial strength.
The historical rank and industry rank for BioGend Therapeutics Co's Quick Ratio or its related term are showing as below:
ROCO:6733'
s Quick Ratio Range Over the Past 10 Years
Min: 2.91 Med: 19.08 Max: 31.5
Current: 17.03
During the past 10 years, BioGend Therapeutics Co's highest Quick Ratio was 31.50. The lowest was 2.91. And the median was 19.08.
ROCO:6733's Quick Ratio is ranked better than 89.51% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs ROCO:6733: 17.03
BioGend Therapeutics Co (ROCO:6733) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BioGend Therapeutics Co Quick Ratio Related Terms
BioGend Therapeutics Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
BioGend Therapeutics Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co (ROCO:6733) has a Quick Ratio of 17.03 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioGend Therapeutics Co and its competitors. This is 11% below median its historical median of 19.08. Over the past decade, BioGend Therapeutics Co's Quick Ratio has ranged from 2.91 to 31.50. According to the industry distribution chart, BioGend Therapeutics Co ranks #148 out of 1411 companies in the Biotechnology industry, placing it in the top 10.5%.
Is BioGend Therapeutics Co's Quick Ratio too high?
BioGend Therapeutics Co's current Quick Ratio of 17.03 is 11% below median its 10-year median of 19.08. Over the past 10 years, this metric has ranged from a low of 2.91 to a high of 31.50. The Biotechnology industry median Quick Ratio is 3.59. BioGend Therapeutics Co's value of 17.03 is 374.4% above this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #148 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #148 out of 1411 companies for Quick Ratio. This places BioGend Therapeutics Co in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. BioGend Therapeutics Co's value of 17.03 is 374.4% above this benchmark. Historically, BioGend Therapeutics Co's own Quick Ratio has ranged from 2.91 to 31.50 over the past decade. While the company's 10-year median is 19.08 vs. the industry median of 3.59, BioGend Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current Quick Ratio of 17.03 is 374.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Quick Ratio is 17.03, which is 11% below median its own 10-year median of 19.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Quick Ratio is 17.03, which is 11% below median its 10-year median of 19.08 and 374.4% above the Biotechnology industry median of 3.59. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Quick Ratio is 17.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Quick Ratio: 17.03 (11% below median its 10-year median of 19.08)
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
Industry Position: 374.4% above the Biotechnology median (#148 of 1411)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
